证券代码：600976 证券简称：健民集团 公告编号：2025-029 健民药业集团股份有限公司 关于董事会完成换届选举 及聘任高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称："公司"）于 2025 年 7 月 30 日召开 2025 年第一次临时股东大会，选举产生第十一届董事会非独立董事 5 名及独立 董事 3 名，与公司职代会联席会选举产生的 1 名职工代表董事共同组成公司第十 一届董事会。 （1）战略与可持续发展委员会 委 员：袁平东、郭云沛、汪思洋、汪俊、胡振波 召集人：袁平东 同日，公司召开第十一届董事会第一次会议，完成董事长、各专门委员会委 员的选举及高级管理人员的聘任等相关事项。现将具体情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 7 月 30 日，公司召开 2025 年第一次临时股东大会，选举裴蓉女士、 汪思洋先生、袁平东先生、汪俊先生、许良先生为公司非独立董事，选举郭云沛 先生、杨智先生、辛金国先生为公司独 ...

证券代码：600976 证券简称：健民集团 公告编号：2025-026 健民药业集团股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 7 月 30 日 (二)股东大会召开的地点：武汉市汉阳区鹦鹉大道 484 号健民集团公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 审议结果：通过 | 1、出席会议的股东和代理人人数 | 251 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 63,832,610 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 41.6122 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 本次股东大会由公司董事会召集，第十届董事会副董事长许良先生主持，会 议采用现场投票与网络投票相结合的方式进行表决， ...

湖北得伟君尚律师事务所 湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年七月三十日 湖北得伟君尚律师事务所 地址:武汉市江汉区建设大道 588 号卓尔国际大厦 20 楼、21 楼 电话: (86 27 8562 0999) 电子邮箱: dewell@ dewellcn. com 关于健民药业集团股份有限公司 2025 年第一次临时股东大会的法律意见书 致:健民药业集团股份有限公司 湖北得伟君尚律师事务所(以下简称本所)接受健民药业集团股份有限公司 (以下简称公司)的委托,指派律师出席公司 2025年第一次临时股东大会,对公司 本次会议进行见证并出具法律意见书。 本所律师依据《公司法》《上市公司股东大会规则》《上海证券交易所上市公 司股东大会网络投票实施细则》(以下简称《网络投票细则》)及《公司章程》的规 定,对公司本次会议的召集与召开程序、召集人及出席会议人员的资格、表决程序 及表决结果的合法有效性发表法律意见。 本所律师根据《证券法》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则(试行)》等规定的要求,严格履行法定职责 ...

证券代码：600976 证券简称：健民集团 公告编号：2025-027 健民药业集团股份有限公司 第十一届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于2025年7月25日发出召开第十一届董事会第一次 会议的通知，并于2025年7月30日在湖北省武汉市汉阳区鹦鹉大道484号公司会议室 召开。会议应出席董事9人，实际出席董事9人，符合《公司法》和《公司章程》的 规定。经全体董事共同推举，本次会议由袁平东先生主持，经到会董事充分讨论， 审议通过如下议案： 1、关于选举公司董事长的议案 同意：9 票 弃权：0 票 反对：0 票 选举袁平东先生为公司第十一届董事会董事长，袁平东先生简历详见公司于 2025年7月15日在中国证券报、证券时报、上海证券报及上海证券交易所网站 （www.sse.com.cn）披露的《健民药业集团股份有限公司关于董事会换届选举的公 告》。 2、关于选举董事会各专门委员会委员及召集人的议案 同意：9 票 弃权：0 票 反对：0 票 详 见 中 国 证 ...

Market Overview - The Shanghai Composite Index closed at 3628.53 points, above the six-month moving average, with an increase of 0.52% [1] - The total trading volume of A-shares reached 1,102.239 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 58 A-shares have surpassed the six-month moving average today [1] - Stocks with significant deviation rates include: - Fenglong Co., Ltd. (5.52%) - Rongke Technology (4.53%) - Keyuan Wisdom (3.66%) [1] Detailed Stock Performance - The following stocks showed notable performance: - Fenglong Co., Ltd. (10.03% increase, turnover rate 7.67%, latest price 17.34 yuan) - Rongke Technology (5.47% increase, turnover rate 6.14%, latest price 18.91 yuan) - Keyuan Wisdom (4.36% increase, turnover rate 8.52%, latest price 25.60 yuan) [1] - Other stocks with positive performance include: - Zhaoyi Innovation (4.47% increase) - Yuntian Lifa (5.06% increase) [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the six-month line include: - Chahua Co., Ltd. - Tangshan Port - China Gold [1]

Summary of Conference Call on National Childcare Subsidy Policy Industry Overview - The conference call discusses the impact of the national childcare subsidy policy on various industries, particularly focusing on the maternal and infant products market, including companies like Feihe, Jianhe International, Aoyou Dairy, and Mengniu Dairy [1][3][5]. Key Points and Arguments 1. **Childcare Subsidy Policy Implementation**: Starting January 1, 2025, the government will provide a monthly subsidy of 300 yuan for children under three years old, applicable to those born after January 1, 2022 [2][6]. 2. **Impact on Maternal and Infant Products Market**: The subsidy is expected to enhance family consumption capacity, benefiting retail companies like Aiyingshi and Haiziwang significantly [1][5]. 3. **Feihe's Financial Performance**: Feihe anticipates a revenue of 20.7 billion yuan in 2024, a 6.2% increase year-on-year, with a net profit of 3.65 billion yuan, up 11% [1][3]. 4. **Jianhe International's Strategy**: The company has diversified its product offerings, with infant nutrition accounting for about half of its revenue. It has expanded its market presence, particularly in lower-tier cities, and aims to increase customer acquisition through promotional events [7][10]. 5. **Aoyou Dairy's Market Position**: Aoyou Dairy leads in the goat milk powder segment and has secured 70% of its raw milk costs, ensuring stable profit margins amid the new policy [8][4]. 6. **Mengniu Dairy's Growth Potential**: Although Mengniu's infant formula business is relatively small, its organic milk powder products are expected to benefit from the subsidy, potentially increasing sales and profitability [9][4]. 7. **Retail Sector Dynamics**: The retail sector, especially maternal and infant products, is poised for growth due to the subsidy, with companies like Aiyingshi and Haiziwang expanding their store networks and product offerings [10][5]. 8. **Consumer Electronics Impact**: Companies like Bear Electric are expected to benefit from the subsidy, with significant growth in maternal and infant appliances, projecting over 40% growth in related product sales [18][3]. 9. **Clothing Market Influence**: The subsidy is likely to boost clothing consumption, particularly in the children's apparel sector, with an estimated increase in spending on children's clothing due to the financial support [19][20]. 10. **Healthcare and Medical Products**: The conference also highlights the potential benefits for healthcare products related to infants, including vaccines and medical services, as the demand for these products is expected to rise with the increase in newborns [16][17]. Other Important Insights - The national subsidy policy represents a significant shift from previous local pilot programs, providing a more inclusive and direct financial support mechanism for families [6][12]. - The policy is expected to stimulate demand across various sectors, including retail, healthcare, and consumer electronics, creating a ripple effect in the economy [12][18]. - Companies are adapting their strategies to leverage the new policy, focusing on expanding product lines and enhancing customer engagement through innovative marketing approaches [7][10]. This summary encapsulates the key discussions and insights from the conference call regarding the national childcare subsidy policy and its implications across various industries.

Group 1 - The first extraordinary general meeting of shareholders for Jianmin Pharmaceutical Group Co., Ltd. is scheduled for July 30, 2025, at 14:00 in Wuhan [1][2] - The meeting will combine on-site voting and online voting through the Shanghai Stock Exchange's shareholder meeting voting system [4][7] - The agenda includes the review and voting on the proposal to amend the company's articles of association [8][9] Group 2 - The meeting will be presided over by Vice Chairman Xu Liang, with Secretary of the Board Zhou Jie recording the minutes [1][2] - Shareholders or their legal representatives must register 30 minutes before the meeting and present necessary identification [6] - The voting process will include a break, followed by the announcement of voting results after the market closes at 15:00 [2][5] Group 3 - The proposed amendments to the articles of association aim to enhance corporate governance by removing the supervisory board and transferring its responsibilities to the audit committee [8][9] - New sections will clarify the roles and obligations of controlling shareholders and actual controllers, as well as the responsibilities of independent directors [9][21] - The amendments will also standardize the procedures for convening shareholder meetings and clarify the qualifications for directors and senior management [9][10]

健民药业集团股份有限公司 二○二五年第一次临时股东大会 会 议 资 料 二○二五年七月三十日 健民药业集团股份有限公司 二○二五年第一次临时股东大会议程 会议记录：周捷董事会秘书 会议出席者：2025 年 7 月 24 日下午收市后在中国证券登记结算有限责任公司上 海分公司登记在册的本公司全体股东或其合法委托的代理人、公司董事、监事及 高级管理人员、公司聘请的律师。 一、 主持人宣布会议开始，介绍现场会议的出席情况； 二、 宣读公司 2025 年第一次临时股东大会会议须知； 现场会议时间 2025 年 7 月 30 日下午 14:00 现场会议地点：武汉市汉阳区鹦鹉大道 484 号健民集团公司会议室 会议召开方式：现场投票和网络投票相结合 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 7 月 30 日至 2025 年 7 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00 ...

Core Viewpoint - The AI Fund for Healthcare Industry Mixed A/B reported a profit of 16.87 million yuan for Q2 2025, with a fund size of 660 million yuan and a net value growth rate of 2.59% [2][14]. Fund Performance - As of July 17, the fund's unit net value was 1.628 yuan, with a three-month growth rate of 8.32%, a six-month growth rate of 10.97%, a one-year growth rate of 12.27%, and a three-year growth rate of -29.52% [2][3]. - The fund's Sharpe ratio over the past three years was -0.2967, ranking 96 out of 105 comparable funds [7]. - The maximum drawdown over the past three years was 43.62%, with the largest single-quarter drawdown occurring in Q1 2024 at 26.26% [10]. Investment Strategy - The fund manager emphasized two main focus areas: 1) Industry logic and cost-effectiveness, with a higher demand for certainty and future potential in stock selection, especially in the A-share market; 2) Directions with improvement expectations, including previously underappreciated areas in the healthcare sector that may see revaluation [2]. - The fund maintained an average stock position of 86.75% over the past three years, peaking at 94.16% in Q1 2024 and dropping to 67.75% in Q1 2025 [13]. Top Holdings - As of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, San You Medical, WuXi AppTec, and others [17].

Core Viewpoint - The candidates for independent director positions at Jianmin Pharmaceutical Group have declared their qualifications and independence, ensuring compliance with relevant laws and regulations [1][6][10]. Group 1: Qualifications - Candidates possess basic knowledge of listed company operations and have over five years of relevant work experience in fields such as law, economics, accounting, finance, or management [1][6]. - The qualifications meet the requirements set forth by various laws and regulations, including the Company Law of the People's Republic of China and the rules established by the China Securities Regulatory Commission [1][8]. Group 2: Independence - Candidates confirm their independence, stating they do not fall under any disqualifying conditions, such as holding significant shares in the company or having close relationships with major shareholders [2][8]. - They have no adverse records, such as administrative penalties from the China Securities Regulatory Commission or being publicly criticized by stock exchanges in the last 36 months [3][9]. Group 3: Commitment - Candidates have undergone qualification reviews by the nomination committee of Jianmin Pharmaceutical Group and have committed to fulfilling their duties independently without influence from the company or its major shareholders [4][10]. - They acknowledge the responsibilities of independent directors and have pledged to comply with all relevant laws and regulations during their tenure [4][10].